MiR-181a contributes to bufalin-induced apoptosis in PC-3 prostate cancer cells

BMC Complementary and Alternative Medicine

Zhe Chen²  Yu-yu Guo²  Yong-bin Meng²  Qun Liu²  Fan-fu Fang¹  Xiao-feng Zhai² 

[1] Department of Rehabilitation Medicine, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China;Department of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China

关键词: Traditional Chinese medicine;    Prostate cancer;    Apoptosis;    Bufalin;    miR-181a;   

Others  :  1220505
DOI  :  10.1186/1472-6882-13-325

 received in 2013-07-21, accepted in 2013-11-18,  发布年份 2013

【 摘 要 】

Background

Bufalin is a major active compound of cinobufacini, which comes from dried toad venom and has been used for treatments of various cancers in China for many years. A number of studies have demonstrated that bufalin can induce apoptosis in some cancers. However, effects and mechanism of bufalin on prostate cancer cells remain unknown.

Methods

Apoptosis assay was measured by the annexin-V/PI flow cytometric assay. Western blot was used to measure Caspase-3 and Bcl-2. qRT-PCR was used to measure the relative expression of miR-181a.

Results

Bufalin was found to induce the expression of miR-181a, a small non-coding RNA believed to induce apoptosis by repressing its target gene, BCL-2. In prostate cancer PC-3cell line, bufalin-induced apoptosis can be largely attenuated by a miR-181a inhibitor, which blocked bufalin-induced Bcl-2 reduction and caspase-3 activation.

Conclusions

Our dataindicatedthat miR-181a mediates bufalin-induced apoptosis in PC-3 cells. Thus, we presented here a new pharmacological mechanism for bufalin in anti-tumor therapy.

【 授权许可】

   
2013 Zhai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Yang LH, Jin XQ, Zhang WD: Studies on the chemical constituents from the skin of Bufo bufo gargarizans cantor. Journal of Shenyang Pharmaceutical University 2000, 17:292-295.
• [2]Qi FH, Li AY, Inagaki Y, Kokudo N, Tamura S, Nakata M, Tang W: Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol 2010, 11:342-349.
• [3]Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, Zhang J, Liu Y: PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 2009, 20:59-64.
• [4]Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS: Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci 2008, 99:2467-2476.
• [5]Sun L, Chen T, Wang X, Chen Y, Wei X: Bufalin induces reactive oxygen species dependent bax translocation and apoptosis in ASTC-a-1 Cells. Evid Based Complement Alternat Med 2011, 2011:249090.
• [6]Han KQ, Huang G, Gu W, Su YH, Huang XQ, Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2007, 13:3374-3379.
• [7]Takai N, Ueda T, Nishida M, Nasu K, Narahara H: Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 2008, 21:637-643.
• [8]Mo YY: MicroRNA regulatory networks and human disease. Cell Mol Life Sci 2012, 69:3529-3531.
• [9]Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
• [10]Li MF, Li J, Ding XF, He M, Cheng SY: microRNA and cancer. AAPS J 2010, 12:309-317.
• [11]Ruan K, Fang XG, Ouyang GL: MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009, 285:116-126.
• [12]Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
• [13]Shi L, Cheng ZH, Zhang JX, Li R, Zhao P, Fu Z, You YP: hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 2008, 1236:185-193.
• [14]Ouyang YB, Lu Y, Yue S, Giffard RG: miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes. Mitochondrion 2011, 12:213-219.
• [15]Bai H, Cao Z, Deng C, Zhou L, Wang C: miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin Oncol 2012, 138:595-602.
• [16]Chen G, Zhu W, Shi DZ, Lv L, Zhang C, Liu P, Hu WX: MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 2010, 23:997-1003.
• [17]Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, et al.: miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70:1793-1803.
• [18]Li H, Hui LL, Xu WL: miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Biochim Biophys Sin (Shanghai) 2012, 44:269-277.
• [19]Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Xu W, Li JY: miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 2012, 33:1294-1301.
• [20]Zhu W, Shan X, Wang TS, Shu YQ, Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127:2520-2529.
• [21]Fei J, Li Y, Zhu X, Luo X: miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS One 2012, 7:e32834.
• [22]Cho WC: MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta 1805, 2009:209-217.
• [23]Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K: Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 1995, 19:549-556.
• [24]Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K: The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 1996, 271:14067-14072.
• [25]Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 1998, 16:779-787.
• [26]Watabe M, Kawazoe N, Masuda Y, Nakajo S, Nakaya K: Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 1997, 57:3097-3100.
• [27]Zhai XF, Chen Z, Li B, Shen F, Fan J, Zhou WP, Yang YK, Xu J, Qin X, Li LQ, Ling CQ: Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial. J Integr Med 2013, 2:90-100.